IGF2BP1 and neoplasm: Overall, it is proposed that IGF2BP1 acts as a phase-separated protein driving the formation of m6A mRNA-stabilized MLOs during tumorigenesis, and future anti-tumor therapy may target these IGF2BP1 condensates through inhibiting IGF2BP1 LLPS or dissolving them.